2020
Classify multicategory outcome in patients with lung adenocarcinoma using clinical, transcriptomic and clinico-transcriptomic data: machine learning versus multinomial models.
Deng F, Shen L, Wang H, Zhang L. Classify multicategory outcome in patients with lung adenocarcinoma using clinical, transcriptomic and clinico-transcriptomic data: machine learning versus multinomial models. American Journal Of Cancer Research 2020, 10: 4624-4639. PMID: 33415023, PMCID: PMC7783755.Peer-Reviewed Original Research
2019
Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study
Shih AR, Uruga H, Bozkurtlar E, Chung J, Hariri LP, Minami Y, Wang H, Yoshizawa A, Muzikansky A, Moreira AL, Mino‐Kenudson M. Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study. Histopathology 2019, 75: 649-659. PMID: 31107973, DOI: 10.1111/his.13922.Peer-Reviewed Original ResearchConceptsSmall lung adenocarcinomaInvasive adenocarcinomaLung adenocarcinomaLung pathologistsElastic stainInterobserver agreementHigh-grade cytologyLow-grade cytologyInvasive component sizeReproducibility of classificationHistological patternFinal diagnosisInvasive componentAdenocarcinomaConsensus conferenceRoutine assessmentInterobserver studyInconsistent classificationPredominant patternSingle caseKappa valuesCytologyPathologists
2014
Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy
JIANG H, WANG H, WANG S, PEI Z, FU Z, FANG C, WANG J, LU Q, WANG E, LI J. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy. Molecular Medicine Reports 2014, 11: 3523-3532. PMID: 25573098, DOI: 10.3892/mmr.2014.3141.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDNA-Binding ProteinsDrug Resistance, NeoplasmEndonucleasesFemaleGene ExpressionHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedMyoD ProteinMyoglobinMyosin Type IIPlatinumPleural Effusion, MalignantPrognosisRibonucleoside Diphosphate ReductaseThymidylate SynthaseTubulinTumor Suppressor ProteinsConceptsExcision repair cross-complementing gene 1Expression of ERCC1Platinum-based chemotherapyMetastatic lung adenocarcinomaLung adenocarcinomaPleural effusionLung Adenocarcinoma Pleural EffusionsPlatinum-based chemotherapy treatmentTumor cellsUntreated lung adenocarcinomasSurvival of patientsMalignant pleural effusionPleural fluid samplesExpression levelsProtein expression levelsWestern blot analysisClinical outcomesPatient survivalLung cancerChemotherapy treatmentLung carcinomaNon-muscle myosin IIPatientsAdenocarcinomaSurvival rateFine‐needle aspiration biopsy of secondary neoplasms of the thyroid gland: A multi‐institutional study of 62 cases
Pusztaszeri M, Wang H, Cibas ES, Powers CN, Bongiovanni M, Ali S, Khurana KK, Michaels PJ, Faquin WC. Fine‐needle aspiration biopsy of secondary neoplasms of the thyroid gland: A multi‐institutional study of 62 cases. Cancer Cytopathology 2014, 123: 19-29. PMID: 25369542, DOI: 10.1002/cncy.21494.Peer-Reviewed Original ResearchConceptsFine-needle aspiration biopsySquamous cell carcinomaThyroid fine-needle aspiration biopsySecondary neoplasmsAncillary studiesAspiration biopsyThyroid glandAccuracy of FNABMean patient ageMean tumor sizeUnknown primary siteUseful ancillary studiesMulti-institutional studyPatient ageInitial diagnosisTumor sizeCell carcinomaClinical historyPrimary tumorMedical recordsDiagnostic difficultiesMean intervalCystic carcinomaPrimary siteAdenocarcinoma